Interesting proteolytic enzyme treatment to help remove eschar in burn victims, which aligns with BARDAs main mission (crises response etc.) They've also supported a couple of antibiotic candidates. Can't see them getting involved in MPC cellular treatments before MSB blaze the trail, and even then the support focus would be acute inflammatory scenarios like ARDS.
On another note, I notice there does exist some promising results for treatment of multiple sclerosis (systemic inflammatory demyelination) with MPCs, an affliction suffered by Chrissy Amphlett.
Cell Therapy News/Articles, page-18214
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |